Aims, Method, Results, Conclusion

Objective: Evaluation of clinical and paraclinical characteristics and treatment results of Paclitaxel-Carboplatin in metastatic thymic carcinoma at K Hospital.

Subjects and Methods: A retrospective study with longitudinal follow-up on patients diagnosed with metastatic thymic carcinoma (AJCC 8th edition), treated with the Paclitaxel-Carboplatin chemotherapy regimen from 2020 to 2024 at K Hospital.

Results: The study included 20 patients with an average age of 56.4 years; 65% were male and 35% were female. ECOG 0 accounted for 70% and ECOG 1 for 30%. The predominant histological type was squamous cell carcinoma (70%). The treatment results showed a response rate of 45% and a disease control rate (DCR) of 75%. The median progression-free survival (mPFS) was 8.7 months after a follow-up of 15.6 months. Hematologic toxicity related to the regimen included anemia in 55% of patients (grade 3 in 5%) and neutropenia in 55% (grade 3 in 10%). Non-hematologic toxicity was commonly observed in the peripheral nervous system (40%) and elevated AST/ALT levels (45%), mainly grades 1 and 2.

Conclusion: The combination of paclitaxel and carboplatin is an effective treatment option for metastatic thymic carcinoma in patients who have not previously received systemic therapy

.